Ram is an accomplished executive with more than 25 years of broad industry experience, a proven track-record in business development and a thorough understanding of the medical isotopes and radiopharmaceuticals landscape.
Prior to his arrival at CNL, Ram served as the Director and Head of Business Development at Jubilant Draxlmage, a global leader in radiopharmaceuticals, where he was responsible for expanding the company’s commercial business into new products and technologies in the nuclear medicine and radiopharmaceutical field. This experience included leading acquisition, investment and licensing initiatives, negotiating business contracts and pursuing strategic partnerships and collaborations. Among his many accomplishments, Ram helped advance key products in the company’s development pipeline to their commercial phase and was instrumental in the growth of its new product portfolio. Ram also shaped, negotiated and helped complete external business partnerships for novel radiopharmaceutical products.
Edouard works with a dedicated team in unravelling the mechanisms underlying the biochemical changes induced in cells and tissues exposed to low doses/low fluences of different radiation types. The goal is to contribute knowledge focussed at alleviating the uncertainty in predicting the health outcomes of occupational exposures, whether in the nuclear industry and health sector or during deep space exploration. Ongoing projects also examine how low dose radiation effects can be harnessed to enhance the effectiveness of cancer therapeutics and in regenerative medicine. He is particularly interested in studying the roles of oxidative metabolism and intercellular communication in radiation-induced adaptive and bystander responses.
Laura BannisterPre-Clinical and Toxicological Research
Laura Bannister is a research scientist in the Radiobiology and Health Branch at CNL and head of the Pre-Clinical and Toxicological Research section. This section includes Veterinary and research staff that oversee operation of CNL’s Biological Research Facility. Work undertaken in this Facility addresses emerging issues of radiation risks related to radioactive exposure of nuclear workers or public environmental or medical exposures, as well as countermeasure development for nuclear accidents. The BRF is currently working toward implementation and accreditation of a Good Laboratory Practice (GLP) Program, which supports commercial animal projects such as pre-clinical toxicity testing, with a focus on the development and testing of pharmaceuticals for Radio-immunotherapy. Dr. Bannister’s current research projects include toxicology of chronic ingestion of natural uranium in drinking water, investigation of molecular signatures linked to lung cancer risk, improved decorporation strategies for system for removal of inhaled radioactive fuel particles.
Candice Didychuk is the Manager of the Radiobiology & Health Branch at the Canadian Nuclear Laboratories, which encompasses facilities and R&D supporting the areas of radiochemistry, medical isotope production & application, dosimetry & health risk, radiation biology and pre-clinical & toxicological research. Candice was a scientist at CNL for 12 years and the Section Head of medical applications, focusing on the pre-clinical evaluation of targeted radionuclide therapies, particularly new Ac-225 drug conjugates for targeted alpha therapeutics of various types of cancer. Her research also captured biokinetic modelling and internal dosimetry of nuclear internal contamination hazards/radionuclides, primarily nuclear fuels and actinides. Previous to this, Candice held research positions at the Lawson Health Research Institute the Sunnybrook Research Institute, where she worked within the medical imaging research community, on the development and preclinical application of multi-purpose nanoparticle contrast agents for cancer targeting, multi-modality imaging and non-invasive cancer therapy.
Samy has led CNL’s R&D in space exploration since joining in 2012. His current research interests are on understanding and quantifying the radiation-induced health consequences associated with space exploration. He also currently serves as external expert to the International Commission on Radiological Protection (ICRP) Task Group 115 on Risk and Dose Assessment for Radiological Protection of Astronauts by invitation of the Canadian Space Agency (CSA).
Holly’s background is in microbiology and immunology, with expertise on pathogenesis and metal metabolism. Her current research interests include examining the effects of low dose radiation on biological systems and carcinogenesis. Holly is currently the principal investigator on projects that examine biochemical and physiological changes in response to low dose beta (i.e. tritium) and gamma ray exposures in breast cancer and colon cancer mouse models. She also leads a project looking at the feasibility of establishing a tissue biobank for CNL-derived, radiological tissues. Lastly, she is part of the Radiation Adverse Outcome Pathway (AOP) Working Group, with members from Health Canada and CNSC, that aims to develop a framework for radiation-mediated AOPs.
Richard RichardsonInternal Dosimetry & Radiobiology
Since starting at CNL in 1993, Dr. Richardson has published extensively on internal dosimetry including tritium and developed a novel explanation of the ‘oxygen effect’, important in radiotherapy. Currently, he is the principal investigator for three major research projects at CNL including assessing the radiation quality of neutrons, now using the NRU reactor. Radiation-induced cataracts is also being studied. He is collaborating with researchers at Health Canada, the Ottawa Health Research Institute and University of Calgary to identify radon biomarkers in human blood. Dr. Richardson has authored over 75 peer-reviewed articles, all available on ResearchGate. He is also an adjunct professor of the Medical Physics Unit at McGill University.
Marilyne is a senior research scientist in the Environment & Waste Technologies Branch. She heads the Environmental Biology and Toxicology section. Marilyne supervises the Chalk River Laboratory (CRL) Aquatic Toxicity Laboratory and she is currently leading the implementation of Good Laboratory Practice for the conduct of pre-clinical health studies at CRL. Marilyne and her team are interested in understanding the effects of chemicals and ionizing radiation on living organisms. The team carries out field and laboratory studies, including multigenerational studies, in the context of single or multiple stressors. By analysing molecular, cellular, organ, organism, or reproductive changes, the team evaluates the risks associated with exposure. Throughout her career at CNL, Marilyne has supervised over 50 students and has taken part in a number of educational initiatives